Pfizer to end development of experimental obesity pill due to elevated liver enzymes
Publishing timestamp: 2023-06-26 12:35:25
Summary
Pfizer is stopping development of its obesity and diabetes pill lotiglipron due to liver enzyme issues, focusing on danuglipron instead. The weight loss industry is seeing a gold rush with new drugs, but questions remain about accessibility and long-term effectiveness. Analysts believe Eli Lilly's pill may have an edge over Pfizer's danuglipron.
Sentiment: MIXED
Keywords: size and weight discrimination, breaking news, business, biotech and pharmaceuticals, lilly drn, health care industry, biotechnology, science, pfizer inc, business news, weight management, pharmaceuticals, novo nordisk a/s,